title: Allelic loss on chromosome 9 in bladder cancer tissues and urine samples detected by blunt-end single-strand DNA conformation polymorphism.
abstract: Allelic loss on chromosome 9 is the most frequent and earliest genetic event in bladder carcinogenesis, and its detection in urine samples would be useful for detecting bladder cancer. A highly sensitive method to detect loss of heterozygosity (LOH) at 5 polymorphic loci on chromosome 9p and 9q was developed by the use of blunt-end single-strand DNA conformation polymorphism (blunt-end SSCP) analysis. Tumor tissues, urine samples and peripheral blood lymphocytes from 34 patients with transitional cell carcinoma of the bladder were analyzed. LOHs on 9p and/or 9q were found in 24 (71%) of 34 tumor samples and 23 (70%) of 33 urine samples, while no allelic loss was detected in 20 urine samples from benign urothelial diseases. The frequency of allelic loss in tumor tissues was 67%, 71% and 80% in the pTa, pT1 and > or = pT2 stages and 50%, 80% and 79% in G1, G2 and G3 tumors, respectively. In comparison with a urine cytological examination, LOH on chromosome 9 was detected in 70% of urine samples diagnosed as transitional cell carcinoma, 67% of those as atypia and 70% of those as no malignant cells. Thus, detection of LOH on chromosome 9 from urine samples by blunt-end SSCP is a more sensitive diagnostic modality than cytologic examination for detecting bladder cancer. It would be useful for postoperative management of bladder cancer, particularly when the allelic loss is revealed in the tumor tissues obtained at first surgery.
authors.affiliation: Division of Clinical Laboratory, National Cancer Center Hospital, Tokyo, Japan.
authors.forename: M
authors.initials: M
authors.lastname: Shigyo
authors.forename: K
authors.initials: K
authors.lastname: Sugano
authors.forename: N
authors.initials: N
authors.lastname: Fukayama
authors.forename: T
authors.initials: T
authors.lastname: Taniguchi
authors.forename: K
authors.initials: K
authors.lastname: Tobisu
authors.forename: H
authors.initials: H
authors.lastname: Fujimoto
authors.forename: N
authors.initials: N
authors.lastname: Doi
authors.forename: M
authors.initials: M
authors.lastname: Niwakawa
authors.forename: K
authors.initials: K
authors.lastname: Shimamura
authors.forename: T
authors.initials: T
authors.lastname: Tsukamoto
authors.forename: T
authors.initials: T
authors.lastname: Sekiya
authors.forename: T
authors.initials: T
authors.lastname: Kakizoe
mesh_terms: D002295:Carcinoma, Transitional Cell / Q000175:diagnosis / Q000235:genetics* / Q000473:pathology / Q000652:urine; D002899:Chromosomes, Human, Pair 9; D005819:Genetic Markers; D006801:Humans; D019656:Loss of Heterozygosity; D009361:Neoplasm Invasiveness; D009367:Neoplasm Staging; D009690:Nucleic Acid Conformation; D018807:Polymorphism, Single-Stranded Conformational; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D001749:Urinary Bladder Neoplasms / Q000175:diagnosis / Q000235:genetics* / Q000473:pathology / Q000652:urine
chemical_list: D005819:Genetic Markers